Neonatal hemochromatosis as one of the manifestations of gestational alloimmune liver disease in fetomaternal isoimmunization

Fetomaternal isoimmunization (alloimmunization) predominantly results in the development of hematological disorders in the neonate, such as hemolytic disease of the Rh blood group and ABO system, as well as alloimmune thrombocytopenia and neutropenia. These pathologies are mediated by maternal IgG antibodies directed against paternally inherited fetal antigens. Gestational alloimmune liver disease (GALD), in contrast, represents a distinct form of fetomaternal isoimmunization, targeting fetal hepatocytes independently of paternal antigenic inheritance In GALD, the transplacental passage of specific maternal antibodies, typically after 18 weeks of gestation, leads to immune- mediated injury of fetal hepatocytes. The most prevalent clinical manifestation of GALD is neonatal hemochromatosis, characterized by acute hepatic failure in the newborn and extrahepatic siderosis. GALD generally presents with nonspecific clinical features, which may include hypoglycemia, severe coagulopathy commonly manifesting as bleeding from various anatomical sites, generalized edema with or without ascites, and oliguria. Recent advances in the understanding of GALD's alloimmune etiology have fundamentally altered therapeutic approaches The use of intravenous immunoglobulin and exchange transfusion has significantly improved survival outcomes, increasing the survival rate without liver transplantation from approximately 20% to 75%. It is imperative to enhance physician awareness across disciplines regarding the alloimmune pathogenesis, diverse clinical presentations, and current treatment tactics for GALD, as well as prophylactic treatment protocols for pregnant women sensitized to fetal hepatocyte antigens. KEYWORDS: neonatal hemochromatosis, gestational alloimmune liver disease, congenital alloimmune hepatitis, fetomaternal isoimmunization, alloimmunization, neonatal acute liver failure, newborns. FOR CITATION: Bem E.V., Chumakova G.N., Panchenko A.S., Myznikova I.V., Tretyakova K.D., Fedorova L.A., Pavlova S.E. Neonatal hemochromatosis as one of the manifestations of gestational alloimmune liver disease in fetomaternal isoimmunization. Russian Journal of Woman and Child Health. 2025;8(2):149–155 (in Russ.). DOI: 10.32364/2618-8430-2025-8-2-9

Authors

Publication Details

Journal
Russian Journal of Woman and Child Health
Published
2025-01-01
DOI
https://doi.org/10.32364/2618-8430-2025-8-2-9
Primary Topic
Blood groups and transfusion
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Neonatal hemochromatosis as one of the manifestations of gestational alloimmune liver disease in fetomaternal isoimmunization

Svetlana E. Pavlova, L.A. Fedorova, Irina V. Myznikova, Г Н Чумакова et al.
Russian Journal of Woman and Child Health
Blood groups and transfusion
article

Neonatal hemochromatosis as one of the manifestations of gestational alloimmune liver disease in fetomaternal isoimmunization

Svetlana E. Pavlova, L.A. Fedorova, Irina V. Myznikova, Г Н Чумакова, А. С. Панченко, E.V. Bem, K.D. Tretyakova
article en

Abstract

Fetomaternal isoimmunization (alloimmunization) predominantly results in the development of hematological disorders in the neonate, such as hemolytic disease of the Rh blood group and ABO system, as well as alloimmune thrombocytopenia and neutropenia. These pathologies are mediated by maternal IgG antibodies directed against paternally inherited fetal antigens. Gestational alloimmune liver disease (GALD), in contrast, represents a distinct form of fetomaternal isoimmunization, targeting fetal hepatocytes independently of paternal antigenic inheritance In GALD, the transplacental passage of specific maternal antibodies, typically after 18 weeks of gestation, leads to immune- mediated injury of fetal hepatocytes. The most prevalent clinical manifestation of GALD is neonatal hemochromatosis, characterized by acute hepatic failure in the newborn and extrahepatic siderosis. GALD generally presents with nonspecific clinical features, which may include hypoglycemia, severe coagulopathy commonly manifesting as bleeding from various anatomical sites, generalized edema with or without ascites, and oliguria. Recent advances in the understanding of GALD's alloimmune etiology have fundamentally altered therapeutic approaches The use of intravenous immunoglobulin and exchange transfusion has significantly improved survival outcomes, increasing the survival rate without liver transplantation from approximately 20% to 75%. It is imperative to enhance physician awareness across disciplines regarding the alloimmune pathogenesis, diverse clinical presentations, and current treatment tactics for GALD, as well as prophylactic treatment protocols for pregnant women sensitized to fetal hepatocyte antigens. KEYWORDS: neonatal hemochromatosis, gestational alloimmune liver disease, congenital alloimmune hepatitis, fetomaternal isoimmunization, alloimmunization, neonatal acute liver failure, newborns. FOR CITATION: Bem E.V., Chumakova G.N., Panchenko A.S., Myznikova I.V., Tretyakova K.D., Fedorova L.A., Pavlova S.E. Neonatal hemochromatosis as one of the manifestations of gestational alloimmune liver disease in fetomaternal isoimmunization. Russian Journal of Woman and Child Health. 2025;8(2):149–155 (in Russ.). DOI: 10.32364/2618-8430-2025-8-2-9

Russian Journal of Woman and Child HealthVol. 8(2)
Openalex Percentile: Top 81%
Blood groups and transfusion
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.